Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Shareholder Meeting (November 2020)
16 slides from Genetic Signatures's shareholder meeting presentation, Nov 20, 2020
Slide 1: Chairman's Address and CEO Presentation at Annual General Meeting
ASX Code: GSS 20 November 2020 Chairman’s Address and CEO Presentation For personal use only at Annual General Meeting Genetic Signatures Limited (ASX: GSS, “Genetic Signatures” or the “Company”), is pleased to release the Chairman’s Address and CEO presentation to be made at the Annual General Meet
Slide 2: Chairman's Address (continued)
consumables and instrumentation has been undertaken to ensure we can rapidly facilitate new customers acquisitions. North America is the largest diagnostics market globally and represents an exciting opportunity to expand in FY21 and beyond. Widespread testing for SARS-CoV-2 has formed a vital part
Slide 3: Further information and About Genetic Signatures
For further information, see our website (www.geneticsignatures.com) or contact us as below: Dr John Melki Peter Manley Chief Executive Officer Chief Financial Officer john.melki@geneticsignatures.com peter.manley@geneticsignatures.com For personal use only T: +61 (0)2 9870 7580 About Genetic Signat
Slide 4: For personal use only
For personal use only AGM Presentation November 2020
Slide 5: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Genetic Signatures Limited (“GSS”). The information contained in this presentation is for information purposes only and has been prepared for use in conjunction with a verbal presentation and should be read in that context. This
Slide 6: Year in Review
Year in Review For personal use only November 2019 Successful $37.5m capital raising March 2020: First shipments and regulatory submission for COVID-19 kit April 2020: CE-IVD received for SARS-CoV-2 kit April 2020: TGA registration of SARS-CoV-2 kit June 2020: Included in S&P/ASX All Ordinaries inde
Slide 7: Impressive YOY Revenue Growth
Impressive YOY Revenue Growth For personal use only Revenue from operations (A$m) 11.3 $11.3m revenues in FY20, • Revenue for FY20 of $11.3m, a +131% on FY19 and 4-year +131% on pcp CAGR of 59% • Growth largely attributed to increasing demand for the SARS-CoV-2 kit • First material sales from EMEA i
Slide 8: FY20 Financial Summary
FY20 Financial Summary For personal use only Year ending Year ending • Revenue of $11.3m ,+131% on pcp driven by A$000 30 June 2020 30 June 2019 demand for SARS-CoV-2 test Revenue from operations 11,263 4,866 ‒ Other revenue includes R&D tax rebate of Other income 2,910 2,327 $2.6m Total revenue 14,
Slide 9: Significant Quarterly Revenue Growth
Significant Quarterly Revenue Growth For personal use only Revenue from operations (A$m) APAC EMEA 10.5 EMEA sales up ~70%, • +585% on pcp and +50% on representing more than previous quarter 15% of 1Q FY21 revenue • Strong demand for tests in 1Q FY21 following second wave of 6.9 COVID-19 • Multiple
Slide 10: Customer Testimonial
For personal use only Customer Testimonial A representative from Royal Marsden Hospital in London explains why they adopted Genetic Signatures EasyScreen products. The video may be accessed via this link https://geneticsignatures.com/au/investors/presentations/ Genetic Signatures is a molecular diag
Slide 11: Asia Pacific Update
Asia Pacific Update For personal use only FY20 revenue increased 116% to $10.2m (FY19: $4.7m) and includes instrument sales of $0.7m Received TGA registration and launched EasyScreen™ SARS-CoV-2 Detection Kit across Australia Underpinned by strong demand for EasyScreen™ SARS-CoV-2 Detection Ki
Slide 12: EMEA Update
EMEA Update For personal use only Europe is a key focus through FY21 and beyond Additional sales and support staff appointed to support growing pipeline of opportunities Direct presence in UK, Netherlands and Germany and distributors in Greece, Ireland, Italy, Spain, Benelux and Poland Achie
Slide 13: North America Update
North America Update For personal use only Largest market opportunity globally, representing an estimated 42% of the global molecular testing market1 Pursuing a direct sales approach with approved laboratories Expanded sales team appointed with strong pedigree in the industry Legally able to
Slide 14: Multiple EasyScreen Kits Targeting Significant Addressable Markets
Multiple EasyScreenTM Kits Targeting Significant Addressable Markets For personal use only Commercial products available… Enteric Respiratory ESBL & CPO STI / Genital TGA / CE-IVD TGA / CE-IVD TGA / CE-IVD Submitted TGA/CE- IVD ~$537m p.a1 ~$627m1 / $6.3bn Emerging market SARS-CoV-22 p.a2 ~A$1.9bn p
Slide 15: Looking Forward
Looking Forward Multiple growth opportunities to be pursued in tandem, creating significant upside potential For personal use only • Focus on securing long-term customer contracts with high throughput pathology Focus on long-term groups, hospitals or government run programs customer contracts • Prov
Slide 16: Contact us
For personal use only Contact us Dr John Melki Genetic Signatures Chief Executive Officer P: +61 (0)2 9870 7580 E: john.melki@geneticsignatures.com Visit us www.geneticsignatures.com Follow us on social media
Genetic Signatures — Shareholder Meeting (November 2020) on 6ix